| P50 | author | Javier Peman | Q43166205 |
| | Guillermo Quindós Andrés | Q43182008 |
| P2093 | author name string | Emilia Cantón | |
| | Elena Eraso | |
| | Alfonso Javier Carrillo-Muñoz | |
| P2860 | cites work | Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature | Q28243864 |
| | In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri | Q28304841 |
| | In vitro activities of four novel triazoles against Scedosporium spp | Q28366842 |
| | Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 |
| | Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program | Q30445376 |
| | Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. | Q30445379 |
| | Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. | Q30447051 |
| | Candida biofilms: an update | Q30475833 |
| | Biofilm formation by Candida dubliniensis | Q30705127 |
| | Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces | Q30799502 |
| | Antifungal drug resistance: limited data, dramatic impact? | Q31040846 |
| | Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins | Q31058690 |
| | Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance | Q33258644 |
| | Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism | Q33716130 |
| | Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole | Q33806807 |
| | Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus | Q33857685 |
| | In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection | Q33859174 |
| | Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). | Q33859215 |
| | Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms | Q33982871 |
| | International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole | Q34041596 |
| | Susceptibility patterns and molecular identification of Trichosporon species | Q34077156 |
| | In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. | Q34110440 |
| | Effects of voriconazole on Cryptococcus neoformans | Q34142180 |
| | Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole | Q34301592 |
| | Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review | Q34391667 |
| | Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 |
| | Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxi | Q34406720 |
| | Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy | Q34430768 |
| | Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints | Q34431984 |
| | Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 |
| | Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro | Q34509773 |
| | Fungal biofilms and drug resistance | Q34540389 |
| | Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. | Q34594642 |
| | In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts | Q34680661 |
| | Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. | Q34680777 |
| | Candidemia in Norway (1991 to 2003): results from a nationwide study | Q34719299 |
| | Candida dubliniensis, a new fungal pathogen | Q34732978 |
| | In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. | Q35103898 |
| | Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. | Q35641428 |
| | Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. | Q35714132 |
| | In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. | Q35759094 |
| | Denture stomatitis: a role for Candida biofilms | Q44970666 |
| | Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases | Q45015455 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. | Q45200724 |
| | Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital | Q45223627 |
| | [In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method]. | Q45257890 |
| | Potential fungicidal effect of voriconazole against Candida spp. | Q45287249 |
| | In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study | Q46276700 |
| | In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates | Q46424835 |
| | Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. | Q46444751 |
| | Fatal Blastoschizomyces capitatus sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece | Q46447097 |
| | In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula | Q46450174 |
| | Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques | Q46480328 |
| | Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole | Q46488457 |
| | Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals | Q46515799 |
| | Voriconazole activity against clinical yeast isolates: a multicentre Italian study | Q46624321 |
| | Scedosporium/Pseudallescheria infections | Q46641539 |
| | In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole | Q46656034 |
| | In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis | Q46656042 |
| | Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer. | Q46699039 |
| | Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole | Q46740583 |
| | Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans | Q46799661 |
| | In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. | Q46801074 |
| | Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole | Q46829679 |
| | Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus | Q46851213 |
| | In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from Northeast, Brazil | Q46876569 |
| | Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 |
| | Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection | Q48177229 |
| | Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine | Q48238445 |
| | In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. | Q50478769 |
| | Candidemia in neonatal intensive care units: Barcelona, Spain. | Q50777995 |
| | Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. | Q51186517 |
| | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 |
| | Candidemia in pediatric patients with congenital heart disease. | Q51245188 |
| | Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center | Q57269730 |
| | Mucormycosis: an emerging disease? | Q57569311 |
| | New resistance mechanisms to azole drugs inAspergillus fumigatusand emergence of antifungal drugs-resistantA. fumigatusatypical strains | Q57651760 |
| | Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India | Q57901969 |
| | Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals | Q59295037 |
| | In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates | Q79399843 |
| | Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults | Q79438783 |
| | Antifungal activities of azole agents against the Malassezia species | Q79558950 |
| | In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods | Q79569522 |
| | In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest | Q79757867 |
| | Voriconazole and multidrug resistance in Candida albicans | Q79787664 |
| | Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital | Q79864121 |
| | Isolation of Issatchenkia occidentalis from the esophagus of a leukemic patient | Q80048216 |
| | Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates | Q80159679 |
| | Biofilm development by clinical isolates of Malassezia pachydermatis | Q80353075 |
| | Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis | Q80374897 |
| | In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis | Q80446270 |
| | [Kodamaea ohmeri fungemia associated with surgery] | Q80552990 |
| | Prevalence of Candida dubliniensis fungemia at a large teaching hospital | Q81162405 |
| | [Pharmacology of azoles] | Q81307359 |
| | Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis | Q83169066 |
| | Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion test | Q35913918 |
| | Second-generation azole antifungal agents | Q36094324 |
| | Emerging fungal diseases | Q36199785 |
| | Changing patterns and trends in systemic fungal infections | Q36239992 |
| | Pseudallescheriasis in the 21st century | Q36278064 |
| | Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature | Q36327963 |
| | Fungal biofilms and antimycotics | Q36352159 |
| | Candidaemia in Europe: epidemiology and resistance | Q36463475 |
| | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations | Q36491819 |
| | Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy | Q36540976 |
| | Aspergillosis: spectrum of disease, diagnosis, and treatment | Q36598035 |
| | Phaeohyphomycosis | Q36598051 |
| | Candida biofilms on implanted biomaterials: a clinically significant problem | Q36624097 |
| | Dematiaceous fungi | Q36738130 |
| | In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata | Q37489291 |
| | In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia | Q38938057 |
| | Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. | Q38954030 |
| | Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit | Q39665005 |
| | Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections | Q40189236 |
| | Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. | Q40458611 |
| | Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani | Q40667778 |
| | In vitro interactions of approved and novel drugs against Paecilomyces spp. | Q40967988 |
| | In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp | Q41091429 |
| | In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. | Q41772012 |
| | In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus | Q41788018 |
| | Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. | Q41842788 |
| | In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. | Q41973262 |
| | Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods | Q42071108 |
| | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest | Q42100738 |
| | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 |
| | Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin | Q42432176 |
| | Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods | Q42708807 |
| | Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. | Q42846025 |
| | In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. | Q42949201 |
| | Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms | Q43415980 |
| | Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species | Q43554708 |
| | In vitro susceptibility of Candida dubliniensis to current and new antifungal agents | Q43651355 |
| | Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. | Q43942557 |
| | The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production | Q43976981 |
| | A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus | Q44357265 |
| | Fusarium infection in hematopoietic stem cell transplant recipients | Q44883924 |
| | Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus | Q44937726 |
| P433 | issue | 3 | |
| P921 | main subject | voriconazole | Q412236 |
| P304 | page(s) | 198-208 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Revista iberoamericana de micologia | Q27719516 |
| P1476 | title | In vitro antifungal activity of voriconazole: New data after the first years of clinical experience | |
| P478 | volume | 24 | |